Compare Adaptive Biotechnologies Corp (ADPT) vs Dover Corp (DOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dover Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Dover Corp trades at $210.47 (market cap $28.82B). The key difference: Dover Corp is far larger — about 8.7× Adaptive Biotechnologies Corp's market cap, and Dover Corp pays a 0.97% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DOV | |
|---|---|---|
Market Cap | $3.33B | $28.82B |
Sector | Health | Industrials |
52-Week High | $22.37 | $233.31 |
52-Week Low | $10.24 | $161.16 |
Enterprise Value | $3.19B | $30.47B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Dover Corporation (DOV) trades at $214.05, up 0.16% on the day, with a bearish technical signal but strong fundamentals including a 13.3% net income margin and consistent earnings beats. Recent news highlights AI data center demand tailwinds and product launches across its subsidiaries. The stock shows healthy profitability with ROE at 15.06% and a P/E of 26.84, while analyst consensus is bullish with a $251 price target.
Outlook remains positive driven by earnings momentum and AI-related growth, though technical weakness and market volatility pose near-term risks. The stock offers value with a 17% upside to consensus target, supported by dividend payments and institutional confidence, but investors should monitor execution on data center opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
